endpoint Clinical, a leader in Integrated Voice Response (IVR)/Integrated Web Response (IWR) systems, announced that PULSE, a fully configurable platform that allows users to design and deploy clinical trial Integrated Response Technology (IRT) systems, saves 40 percent on the development time of clinical trials. This time and cost savings stems from PULSE’s ability to provide pre-validated programs so developers do not have to spend valuable time reconfiguring studies. For some studies, endpoint will deliver a validated study program in just four weeks rather than eight weeks.
endpoint’s PULSE engine gives more control to Clinical Program Managers by allowing them to perform mid-study changes on the fly. Because endpoint’s platform contains pre-validated programs, clinical trials can move ahead at a more rapid rate due to project managers having access to the configurable design elements available by PULSE rather than relying on custom development for each change.
“PULSE literally puts the power in the hands of the program manager rather than going through the development team which consumes more time,” said Jonathan Dole, co-founder and CEO, endpoint. “Shaving weeks off of the development process for the clinical trial process, PULSE is the holy grail for pharmaceutical and medical companies who want to streamline the trials they sponsor.”
Based on a data-driven platform, PULSE is a rules-based engine that quickly and accurately deploys IRT systems with the highest degree of quality and a vast set of features. By utilizing the pre-validated functions in the PULSE engine, clinical studies are deployed much more quickly and at much less cost. The cost savings is then passed on to the sponsor through a simplified “Not-to-Exceed” pricing structure in which only the active number of sites and patents are billed and there are no telecom fees for the length of the study/trial. PULSE simultaneously deploys systems that can be accessed via the phone, web or mobile device.
“The ultimate benefit from endpoint’s PULSE system aside from saving both time and money is that it allows sponsors of smaller, Phase 1 studies to deploy a robust IVR/IWR system to manage the study,” said David Joseph-Lacagnina, VP business development, endpoint. “Access to a technology platform that offers them total control of the process is a huge selling point. “This is a great thing for the industry and for sponsors who will ultimately benefit from comprehensive studies that save time and money while allowing for much more control.”
Date: February 9, 2010
Source: endpoint Clinical
